Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and improving quality-of-life. The combination of recent preclinical and clinical data suggests that localized cardiac RT is relatively safe and has positive conductive and anti-proliferative effects in the "sick" heart. In this Phase 1 study, the investigators aim to assess the feasibility and safety of 5 Gy whole heart radiotherapy in six (6) ESHF participants with limited options for further medical therapy to control their disease. The investigators hypothesize that 5 Gy whole heart radiotherapy can improve LVEF and decrease blood markers of heart failure and inflammation including B-type natriuretic peptide (BNP), C-reactive protein (CRP), and troponins, while also having a very tolerable side effect profile.
- EligibilityCriteria: Inclusion Criteria:  at least 65 years of age End-stage heart failure NYHA class 3-4, LVEF ≤ 30% on maximum medical therapy with progressive symptoms/disease as defined by their primary cardiologist  Exclusion Criteria:  previous RT in the treatment field that precludes further RT active connective tissue disease interstitial pulmonary fibrosis Participants who are unable to be positioned in a manner where treatment can be safely delivered - HealthyVolunteers: No - Gender: All - MinimumAge: 65 Years - StdAgeList: Older Adult